In the MONARCHE trial (adjuvant abemaciclib in high risk HR + HER2-breast cancer), VTE were more frequent with abemaciclib plus endocrine therapy (2.3 %) versus endocrine therapy alone (0.5 %) [1]. This evidence concerns the gene ERBB2 and breast cancer.